2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
CA 2396590 C · Owner: Novartis Ag · Inventors: Manley, Paul William; Bold, Guido
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of 2-amino-nicotinamide derivatives of formula (I) wherein n is from 1 up to and including 6; W is O or S; R1 and R3 represent independently of each other hydrogen lower alkyl or lower , acyl; , R2 represents a cycloalkyl group an aryl group, or a mono- or bicyclic heteroaryl , group comprising one or more ring nitrogen atoms and 0 1 or 2 heteroatoms , independently, from each other selected from the group consisting of oxygen and sulfur which groups in each case are unsubstituted or mono- or polysubstituted; R and R' are independently of each other hydrogen or lower alkyl; X represents an aryl , group, or a mono- or bicyclic heteroaryl group comprising …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 2001 and granted March 1, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.